As a GLP-1 receptor agonist, semaglutide works by mimicking the incretin hormone GLP-1
FDA (2022) FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections
When commercial serums advertise 10% peptides, theyre usually referring to 10% of a solution containing only a few milligrams of actual raw peptide by weight

You should contact your GP or diabetes specialist nurse if: Weakness is severe, persistent, or progressively worsening You experience recurrent episodes of hypoglycaemia (blood glucose below 4 mmol/L) [13] Weakness is accompanied by chest pain, shortness of breath, or palpitations You have significant muscle weakness affecting mobility or daily activities Gastrointestinal symptoms (nausea, vomiting, diarrhoea) are severe or prolonged, leading to dehydration You notice unexplained weight loss beyond what is expected with treatment You develop symptoms of pancreatitis (severe, persistent abdominal pain radiating to the back) You experience right upper quadrant pain, fever or jaundice (possible gallbladder issues) You notice new or sudden changes in your vision You have reduced urine output or confusion (possible dehydration or kidney problems) Contact NHS 111 for urgent but non-life-threatening concerns, or seek emergency care (call 999 or attend A&E) if: You experience symptoms of severe hypoglycaemia with confusion, loss of consciousness, or seizures You have signs of severe dehydration (extreme dizziness, reduced urine output, rapid heartbeat) You develop symptoms suggestive of diabetic ketoacidosis (though rare with GLP-1 receptor agonists like Ozempic), such as abdominal pain, vomiting, rapid breathing, and ketones in blood or urine [23] [24] Your healthcare provider can conduct a thorough assessment, including blood tests to evaluate glucose control, electrolyte balance, kidney function, and thyroid status
